

The field of sleep medicine witnessed substantial progress in 2025, spanning from new treatments for narcolepsy and sleep apnoea, and new guidelines for restless legs syndrome, to new imaging biomarkers of neurodegeneration emerging from the study of rapid-eye-movement sleep behaviour disorder (RBD). These advances strengthened the translational connections between molecular mechanisms and clinical neurology.
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet
Neurology
|11th Mar, 2026
|The Lancet